| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 2000;119:429-439
© 2000 Mosby, Inc.
GENERAL THORACIC SURGERY |
From the Bimodality Lung Oncology Team (BLOT).
Supported in part by a grant from Bristol-Myers Squibb. All authors had research/grant support from Bristol-Myers Squibb for conduct of this trial. Drs Pisters, Ginsberg, Mault, and Bunn receive honoraria from Bristol-Myers Squibb for educational lectures.
Address for reprints: Katherine M. W. Pisters, MD, Department of Thoracic/Head & Neck Medical Oncology, U.T. M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 80, Houston, TX 77030-4095 (E-mail address: kpisters{at}mdanderson.org ).
Objective: This phase II trial assessed the feasibility, as measured by response rate, toxicity, resectability rate, and surgical morbidity and mortality rates, of perioperative paclitaxel and carboplatin chemotherapy in patients with early-stage non–small cell lung carcinoma.
Methods: All patients required negative mediastinoscopy results and adequate medical parameters to undergo induction chemotherapy and an operation. Superior sulcus patients were excluded. Chemotherapy consisted of paclitaxel 225 mg/m2 over 3 hours and carboplatin (area under the curve = 6) every 21 days for 2 cycles preoperatively. Three postoperative cycles of chemotherapy were planned for patients undergoing complete resection.
Results: Between June 1996 and July 1998, 94 patients were entered into the study. Sixty-five (69%) were men, and the median age was 64 years (range, 34-79 years). After induction chemotherapy, 53 of 94 (56%; 95% confidence interval, 46%-67%) had a major objective response, 88 (94%) underwent surgical exploration, and 81 (86%; 95% confidence interval, 78%-92%) underwent complete resection. Reasons for not undergoing an operation included disease progression (n = 3), clinically unresectable status (n = 1), death (n = 1), and patient lost to follow-up (n = 1). Two postoperative deaths occurred. Six (6%; 95% confidence interval, 0%-13%) pathologic complete responses were observed. Ninety (96%) patients received the planned preoperative chemotherapy versus 45% receiving postoperative chemotherapy. No unexpected chemotherapy or surgical morbidity occurred. The 1-year survival is currently estimated at 85%, and the median survival has not yet been reached.
Conclusions: Induction chemotherapy with paclitaxel and carboplatin is feasible and produces a high response rate with acceptable morbidity and mortality rates in early-stage non–small cell lung carcinoma. A prospective randomized trial comparing 3 cycles of induction chemotherapy and surgery with surgery alone in early-stage non–small cell lung carcinoma is planned.
This article has been cited by other articles:
|
|
 |
|
  A. J. Wozniak and S. M. Gadgeel Review: Adjuvant therapy for resected non-small cell lung cancer Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 109 - 118. [Abstract] [PDF]
|
|
|
|
 |
|
 L. M. Krug, H. I. Pass, V. W. Rusch, H. L. Kindler, D. J. Sugarbaker, K. E. Rosenzweig, R. Flores, J. S. Friedberg, K. Pisters, M. Monberg, et al. Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma J. Clin. Oncol., June 20, 2009; 27(18): 3007 - 3013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Hicks Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 31S - 42S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Cerfolio, A. S. Bryant, V. L. Jones, and R. M. Cerfolio Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival Eur. J. Cardiothorac. Surg., April 1, 2009; 35(4): 718 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Stiles, E. L. Servais, P. C. Lee, J. L. Port, S. Paul, and N. K. Altorki Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ramnath, T. L. Demmy, A. Antun, N. Natarajan, C. E. Nwogu, G. M. Loewen, and M. E. Reid Pneumonectomy for Bronchogenic Carcinoma: Analysis of Factors Predicting Survival Ann. Thorac. Surg., May 1, 2007; 83(5): 1831 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. van Meerbeeck, G. W. P. M. Kramer, P. E. Y. Van Schil, C. Legrand, E. F. Smit, F. Schramel, V. C. Tjan-Heijnen, B. Biesma, C. Debruyne, N. van Zandwijk, et al. Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer J Natl Cancer Inst, March 21, 2007; 99(6): 442 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Petersen, D. Pham, E. M. Toloza, W. R. Burfeind, D. H. Harpole Jr, S. I. Hanish, and T. A. D'Amico Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. Ann. Thorac. Surg., July 1, 2006; 82(1): 214 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brunelli, F. Xiume', M. Al Refai, M. Salati, R. Marasco, and A. Sabbatini Gemcitabine-Cisplatin Chemotherapy Before Lung Resection: A Case-Matched Analysis of Early Outcome Ann. Thorac. Surg., June 1, 2006; 81(6): 1963 - 1968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al. Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ramnath, E. Sommers, L. Robinson, C. Nwogu, A. Sharma, A. Cantor, and G. Bepler Phase II Study of Neoadjuvant Chemotherapy With Gemcitabine and Vinorelbine in Resectable Non-small Cell Lung Cancer Chest, November 1, 2005; 128(5): 3467 - 3474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio, A. S. Bryant, S. A. Spencer, and A. A. Bartolucci Pulmonary Resection After High-Dose and Low-Dose Chest Irradiation Ann. Thorac. Surg., October 1, 2005; 80(4): 1224 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Visbal, N. B. Leighl, R. Feld, and F. A. Shepherd Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer Chest, October 1, 2005; 128(4): 2933 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Farray, N. Mirkovic, and K. S. Albain Multimodality Therapy for Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3257 - 3269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Port, R. J. Korst, P. C. Lee, M. A. Levin, D. E. Becker, R. Keresztes, and N. K. Altorki Surgical Resection for Residual N2 Disease After Induction Chemotherapy Ann. Thorac. Surg., May 1, 2005; 79(5): 1686 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Choi, D.-Y. Oh, J. H. Kwon, S.-I. Kim, S. R. Park, J.-Y. Bak, J. H. Kim, D.-W. Kim, Y. T. Kim, T.-Y. Kim, et al. Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 6 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio, A. S. Bryant, T. S. Winokur, B. Ohja, and A. A. Bartolucci Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer Ann. Thorac. Surg., December 1, 2004; 78(6): 1903 - 1909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Endo, Y. Sato, T. Hasegawa, K. Tetsuka, S. Otani, N. Saito, Y. Tezuka, and Y. Sohara Preoperative chemotherapy increases cytokine production after lung cancer surgery Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 787 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Downey, T. Akhurst, M. Gonen, A. Vincent, M. S. Bains, S. Larson, and V. Rusch Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection J. Clin. Oncol., August 15, 2004; 22(16): 3255 - 3260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Borczuk, L. Shah, G. D. N. Pearson, K. L. Walter, L. Wang, J. H. M. Austin, R. A. Friedman, and C. A. Powell Molecular Signatures in Biopsy Specimens of Lung Cancer Am. J. Respir. Crit. Care Med., July 15, 2004; 170(2): 167 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Trodella, P. Granone, S. Valente, S. Margaritora, G. Macis, A. Cesario, R. M. D'Angelillo, V. Valentini, G. M. Corbo, V. Porziella, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging Ann. Onc., March 1, 2004; 15(3): 389 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Scagliotti and A. T. Turrisi III Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer Oncologist, August 1, 2003; 8(4): 361 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.K. Altorki, R.S. Keresztes, J.L. Port, D.M. Libby, R.J. Korst, D.B. Flieder, C.A. Ferrara, D.F. Yankelevitz, K. Subbaramaiah, M.W. Pasmantier, et al. Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., July 15, 2003; 21(14): 2645 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sawabata, H. Hirano, M. Inoue, Y. Okumura, H. Asada, S.-i. Takeda, and H. Maeda Immunohistochemical analysis of resectedclinical Stage I pulmonary adenocarcinomas withhigh preoperative levels of serumcarcinoembryonic antigen Ann. Thorac. Surg., July 1, 2003; 76(1): 203 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Betticher, S.-F. Hsu Schmitz, M. Totsch, E. Hansen, C. Joss, C. von Briel, R. A. Schmid, M. Pless, J. Habicht, A. D. Roth, et al. Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non-Small-Cell Lung Cancer: A Multicenter Phase II Trial J. Clin. Oncol., May 1, 2003; 21(9): 1752 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Marra, L. Hillejan, G. Zaboura, T. Fujimoto, D. Greschuchna, and G. Stamatis Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 543 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Scott, J. Howington, and B. Movsas Treatment of Stage II Non-small Cell Lung Cancer Chest, January 1, 2003; 123 (2009): 188S - 201S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kameyama, C.-l. Huang, E. Hayashi, D. Liu, T. Okamoto, Y. Yamamoto, and H. Yokomise Induction chemotherapy before operation for multiple endobronchial squamous cell carcinoma of the lung Ann. Thorac. Surg., October 1, 2002; 74(4): 1008 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sawabata, M. Ohta, S.-i. Takeda, H. Hirano, Y. Okumura, H. Asada, and H. Maeda Serum carcinoembryonic antigen level in surgically resected clinical stage i patients with non-small cell lung cancer Ann. Thorac. Surg., July 1, 2002; 74(1): 174 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Martin, R. J. Ginsberg, E. S. Venkatraman, M. S. Bains, R. J. Downey, R. J. Korst, M. G. Kris, and V. W. Rusch Long-Term Results of Combined-Modality Therapy in Resectable Non-Small-Cell Lung Cancer J. Clin. Oncol., April 15, 2002; 20(8): 1989 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Depierre, B. Milleron, D. Moro-Sibilot, S. Chevret, E. Quoix, B. Lebeau, D. Braun, J.-L. Breton, E. Lemarie, S. Gouva, et al. Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non-Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2002; 20(1): 247 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Novoa, G. Varela, and M.F. Jimenez Morbidity after surgery for non-small cell lung carcinoma is not related to neoadjuvant chemotherapy Eur. J. Cardiothorac. Surg., October 1, 2001; 20(4): 700 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Martin, R. J. Ginsberg, A. Abolhoda, M. S. Bains, R. J. Downey, R. J. Korst, T. L. Weigel, M. G. Kris, E. S. Venkatraman, and V. W. Rusch Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy Ann. Thorac. Surg., October 1, 2001; 72(4): 1149 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Roberts, C. Eustis, R. Devore, D. Carbone, H. Choy, and D. Johnson Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer Ann. Thorac. Surg., September 1, 2001; 72(3): 885 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Putnam Jr The anatomic basis for lung cancer staging: the end of the beginning? Ann. Thorac. Surg., June 1, 2001; 71(6): 1757 - 1758. [Full Text] [PDF]
|
|
|
|
|
|
M. P. Siegenthaler, K. M. Pisters, K. W. Merriman, J. A. Roth, S. G. Swisher, G. L. Walsh, A. A. Vaporciyan, W. R. Smythe, and J. B. Putnam Jr Preoperative chemotherapy for lung cancer does not increase surgical morbidity Ann. Thorac. Surg., April 1, 2001; 71(4): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bueno, W. G. Richards, S. J. Swanson, M. T. Jaklitsch, J. M. Lukanich, S. J. Mentzer, and D. J. Sugarbaker Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival Ann. Thorac. Surg., December 1, 2000; 70(6): 1826 - 1831. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
